Sight Sciences' (SGHT) Neutral Rating Reiterated at Piper Sandler

Piper Sandler reiterated their neutral rating on shares of Sight Sciences (NASDAQ:SGHT - Free Report) in a research note published on Friday morning, Benzinga reports. Piper Sandler currently has a $6.00 target price on the stock, up from their previous target price of $5.00.

Separately, Needham & Company LLC restated a hold rating on shares of Sight Sciences in a research note on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $4.70.

Sight Sciences Stock Performance

SGHT stock traded up $0.35 during midday trading on Friday, hitting $5.96. 92,264 shares of the company traded hands, compared to its average volume of 217,762. Sight Sciences has a twelve month low of $1.04 and a twelve month high of $11.00. The company has a quick ratio of 12.65, a current ratio of 13.29 and a debt-to-equity ratio of 0.26. The business has a 50 day simple moving average of $5.08 and a 200-day simple moving average of $4.17. The stock has a market capitalization of $295.32 million, a price-to-earnings ratio of -5.02 and a beta of 2.73.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. The company had revenue of $18.75 million for the quarter, compared to the consensus estimate of $18.70 million. During the same quarter last year, the company posted ($0.35) earnings per share. As a group, equities research analysts predict that Sight Sciences will post -1.04 earnings per share for the current year.

Insider Transactions at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Badawi sold 12,571 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the sale, the chief executive officer now owns 5,750,729 shares in the company, valued at approximately $29,213,703.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,129 shares of company stock worth $173,375. Insiders own 27.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Eagle Investment Management LLC lifted its holdings in shares of Sight Sciences by 45.6% during the third quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company's stock valued at $1,979,000 after acquiring an additional 183,912 shares during the period. Boston Partners lifted its holdings in shares of Sight Sciences by 3.1% during the third quarter. Boston Partners now owns 331,776 shares of the company's stock valued at $1,117,000 after acquiring an additional 9,919 shares during the period. Swiss National Bank lifted its holdings in shares of Sight Sciences by 19.5% during the third quarter. Swiss National Bank now owns 69,314 shares of the company's stock valued at $234,000 after acquiring an additional 11,300 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Sight Sciences by 100.0% during the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company's stock valued at $202,000 after acquiring an additional 30,000 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Sight Sciences by 180.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company's stock valued at $62,000 after acquiring an additional 7,764 shares during the period. 55.51% of the stock is owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.